Hims & Hers names ex-FDA official Deb Autor as first policy chief
Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, the telehealth firm said on Monday.
Hims & Hers Bets on Lab Testing to Boost Growth
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'll support growth.
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates
Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.06 per share a year ago.
Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript
Hims & Hers Health, Inc. ( HIMS ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Bill Newby Andrew Dudum - Co-Founder, Chairman & CEO Yemi Okupe - Chief Financial Officer Conference Call Participants Justin Patterson - KeyBanc Capital Markets Inc., Research Division Maria Ripps - Canaccord Genuity Corp., Research Division Craig Hettenbach - Morgan Stanley, Research Division Brian Tanquilut - Jefferies LLC, Research Division Eric Percher - Nephron Research LLC Ryan MacDonald - Needham & Company, LLC, Research Division Jungwon Kim - TD Cowen, Research Division Presentation Operator Thank you for standing by. My name is Eric, and I will be your conference operator today.
Hims & Hers Scales AI-Driven Personalized Health and Wellness
HIMS scales AI-driven care with new hormonal health lines, global expansion plans and a $870 million funding boost.
Struggling Healthcare Stock Ripe For Bull Notes
Shares of Hims & Hers Health (HIMS) are headed for their fourth-straight daily drop, down 2.4% to trade at $45.53 at last check, as investors look ahead to the company's third quarter results, due out after the close Monday, Nov. 3. Since hitting a February record high of $72.98, the stock has staged several rallies that have run out of steam around $65.
